Summary.-One hundred and ninety-one adults with acute myelogenous leukaemia were treated with combination chemotherapy consisting of daunorubicin and cytosine arabinoside (Barts III). Sixty-three patients achieved remission and were admitted to one of 3 trials of active immunotherapy: immunotherapy alone, immunotherapy and maintenance chemotherapy or neither of these. All patients had weekly clinical and blood examination and monthly marrow examination. Reinduction chemotherapy was given as soon as relapse was diagnosed in the marrow. The most striking observation was that immunotherapy was associated with easy and repeated reinduction of remission and marked prolongation of survival after first relapse when compared with immunotherapy plus chemotherapy. The possible reasons for this and the value of immunotherapy are discussed in relation to the third trial still in progress which includes 2 maintenance arms, immunotherapy alone and surveillance only. The present communication describes our experience over a 6-year period of 3 trials of active immunotherapy in AML in which immunotherapy has been associated with relatively short first remissions but easy second and subsequent remission with long post-relapse survival and an excellent quality of life.
IN 1971 we began a trial of active immunotherapy for acute myelogenous leukaemia (AML) using a regime of remission induction and maintenance which was based upon that but included routine monthly diagnostic marrow examination for the early detection of relapse. We found that second remissions were the rule (6/7 patients), while third and subsequent remissions commonly occurred (Freeman et al., 1973) , in contrast to the general experience that relativelv few patients achieved second remission in adult AML (Wiernik and Serpick, 1970; Bailey et al., 1971; Crowther et al., 1973; Powles, 1973; Powles et al., 1973 Powles et al., , 1977 . There are few reports of third remissions (Whittaker and Slater, 1977 examination was repeated within 2 weeks. A blast count > 8 0 was taken as definite indication of relapse, even in the absence of clinical and peripheral blood changes. Immunotherapy with irradiated allogeneic AML blast cells and BCG (Glaxo) was administered at weekly intervals as described previously (Freeman et al., 1973) .
RESULTS
One hundred and ninety-one patients have been entered into the Manchester AML trials since October 1971, and 63 have achieved remission, an overall induction rate of 33%/'. Fig. 1 is a life table of survival from presentation for patients who remitted, using the 5 protocols summarized in Table I. Table II summarizes the data relevant to length of first remission, frequency of second and subsequent remissions and duration of survival after first relapse. Seven patients are still in their first remission and 10 patients have survived more than 2 years from first relapse. Of the 9 surviving longest, 2 have survived for 5 years, 2 over 4 years and the rest have survived over 3 years. The survival curves in Fig. 1 do not show any statistical difference between the different arms of treatment.
Amongst the 39 patients who achieved first remission but who have since died, the average duration of survival following first relapse was > 8 months. Although there was no significant difference in overall survival after relapse, including living patients in the second trial, the average times between first relapse and death was 290-7 days for patients receiving immunotherapy only and 145-6 for those receiving immunotherapy with maintenance chemotherapy (Fig. 2) Cytosine arabinoside (Ara C) 2-0 mg/kg daily by i.v. pulse
Barts III induction Days 1-5 f
B=Cyclophosphamide 200 mg/M2 weekly for 6 weeks.
Thioguanine 2-5 mg/kg daily for 6 weeks. C = 5-day course of Arc C + Thioguanine and A alternating monthly, except that dosage of thioguanine was 2-0 mg/kg (laily orally (Barts chemotherapy maintenance). I= 109 irradiated allogeneic leukaemic cells plus 106 Glaxo BCG (Freeman et al., 1973 Immunotherapy appears to prolong first remission Powles et al., 1977) , facilitate reinduction (Freeman et al., 1973) and lengthen postrelapse survival (Powles et al., 1977 
